Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457


Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.

Hari P, Khandelwal P, Smoyer WE.

Pediatr Nephrol. 2019 Jul 13. doi: 10.1007/s00467-019-04301-y. [Epub ahead of print]


Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study.

Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Ahn KW, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.

Transpl Infect Dis. 2019 Jul 12:e13145. doi: 10.1111/tid.13145. [Epub ahead of print]


Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M.

JAMA Netw Open. 2019 Jul 3;2(7):e196476. doi: 10.1001/jamanetworkopen.2019.6476.


Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.

Gupta A, Bagri NK, Tripathy SK, Barwad A, Phulware RH, Hari P.

Rheumatol Int. 2019 Jul 4. doi: 10.1007/s00296-019-04363-z. [Epub ahead of print] Review.


Risk factors for orbital implant exposure after evisceration: A case control study of 93 patients.

Gupta R, Hari P, Khurana B, Kiran A.

Indian J Ophthalmol. 2019 Jul;67(7):1148-1151. doi: 10.4103/ijo.IJO_1813_18.


Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.

Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A.

Front Immunol. 2019 Jun 7;10:1282. doi: 10.3389/fimmu.2019.01282. eCollection 2019.


Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH.

Leuk Res. 2019 Aug;83:106172. doi: 10.1016/j.leukres.2019.106172. Epub 2019 Jun 17.


Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.

Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S.

Haematologica. 2019 Jun 20. pii: haematol.2019.221127. doi: 10.3324/haematol.2019.221127. [Epub ahead of print]


Color Stability of a New Rice Husk Composite in Comparison with Conventional Composites after Exposure to Commonly Consumed Beverages in Malaysia.

Raja KK, Hari P, Chin MQK, Singbal K, Fareez IM.

Int J Dent. 2019 May 2;2019:9753431. doi: 10.1155/2019/9753431. eCollection 2019.


The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype.

Hari P, Millar FR, Tarrats N, Birch J, Quintanilla A, Rink CJ, Fernández-Duran I, Muir M, Finch AJ, Brunton VG, Passos JF, Morton JP, Boulter L, Acosta JC.

Sci Adv. 2019 Jun 5;5(6):eaaw0254. doi: 10.1126/sciadv.aaw0254. eCollection 2019 Jun.


Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.

Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A.

J Clin Apher. 2019 Jun 7. doi: 10.1002/jca.21711. [Epub ahead of print]


Inhibition of the 60S ribosome biogenesis GTPase LSG1 causes endoplasmic reticular disruption and cellular senescence.

Pantazi A, Quintanilla A, Hari P, Tarrats N, Parasyraki E, Dix FL, Patel J, Chandra T, Acosta JC, Finch AJ.

Aging Cell. 2019 Aug;18(4):e12981. doi: 10.1111/acel.12981. Epub 2019 May 31.


Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P.

Front Genet. 2019 May 8;10:424. doi: 10.3389/fgene.2019.00424. eCollection 2019. Review.


Glomerular C4d Staining Does Not Exclude a C3 Glomerulopathy.

Singh G, Singh SK, Nalwa A, Singh L, Pradeep I, Barwad A, Sinha A, Hari P, Bagga A, Bagchi S, Agarwal SK, Dinda AK.

Kidney Int Rep. 2019 Feb 13;4(5):698-709. doi: 10.1016/j.ekir.2019.02.006. eCollection 2019 May.


Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond.

Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J.

Biol Blood Marrow Transplant. 2019 May 6. pii: S1083-8791(19)30286-1. doi: 10.1016/j.bbmt.2019.05.002. [Epub ahead of print]


Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model.

Krock E, Millecamps M, Anderson KM, Srivastava A, Reihsen TE, Hari P, Sun YR, Jang SH, Wilcox GL, Belani KG, Beebe DS, Ouellet J, Pinto MR, Kehl LJ, Haglund L, Stone LS.

EBioMedicine. 2019 May;43:487-500. doi: 10.1016/j.ebiom.2019.04.032. Epub 2019 Apr 30.


Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations.

Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D.

Biol Blood Marrow Transplant. 2019 Apr 17. pii: S1083-8791(19)30235-6. doi: 10.1016/j.bbmt.2019.04.012. [Epub ahead of print] Review.


Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology.

Pediatr Nephrol. 2019 Aug;34(8):1465-1482. doi: 10.1007/s00467-019-04233-7. Epub 2019 Apr 15.


When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.

Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e251-e258. doi: 10.1016/j.clml.2019.02.008. Epub 2019 Mar 8. No abstract available.


Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.

Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M.

Biol Blood Marrow Transplant. 2019 Apr 6. pii: S1083-8791(19)30226-5. doi: 10.1016/j.bbmt.2019.04.003. [Epub ahead of print]


A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A.

Biol Blood Marrow Transplant. 2019 Apr 6. pii: S1083-8791(19)30228-9. doi: 10.1016/j.bbmt.2019.04.005. [Epub ahead of print]


Altered Peripheral Blood Leucocyte Phenotype and Responses in Healthy Individuals with Homozygous Deletion of FHR1 and FHR3 Genes.

Bhasym A, Gurjar BS, Prabhu S, Puraswani M, Khandelwal P, Saini H, Saini S, Chatterjee P, Bal V, George A, Coshic P, Patidar G, Hari P, Sinha A, Bagga A, Rath S, Guchhait P.

J Clin Immunol. 2019 Apr;39(3):336-345. doi: 10.1007/s10875-019-00619-2. Epub 2019 Apr 3.


Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies.

Shah NN, Maatman T, Hari P, Johnson B.

Front Oncol. 2019 Mar 12;9:146. doi: 10.3389/fonc.2019.00146. eCollection 2019. Review.


Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.

Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A.

Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):10-14. doi: 10.1016/j.hemonc.2018.05.002. Epub 2018 Jun 28.


Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation.

Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1456-1464. doi: 10.1016/j.bbmt.2019.03.013. Epub 2019 Mar 14.


Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]


Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.

Dhakal B, Pagenkopf A, Umair Mushtaq M, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F.

Leuk Lymphoma. 2019 Mar 8:1-5. doi: 10.1080/10428194.2019.1585836. [Epub ahead of print] No abstract available.


C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.

Bharati J, Bhatia D, Khandelwal P, Gupta N, Sinha A, Khadgawat R, Hari P, Bagga A.

Indian J Pediatr. 2019 Jun;86(6):555-557. doi: 10.1007/s12098-019-02909-4. Epub 2019 Mar 5.


Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.


Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.

Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1099-1106. doi: 10.1016/j.bbmt.2019.02.015. Epub 2019 Feb 20.


Thermo-Optical Properties of Cobalt-Doped Zinc Oxide (ZnO) Nanorods.

Kaphle A, Echeverria E, Mcllroy DN, Roberts K, Hari P.

J Nanosci Nanotechnol. 2019 Jul 1;19(7):3893-3904. doi: 10.1166/jnn.2019.16491.


Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study.

Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M.

Bone Marrow Transplant. 2019 Jan 29. doi: 10.1038/s41409-019-0457-9. [Epub ahead of print]


Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jul;33(7):1736-1746. doi: 10.1038/s41375-019-0384-1. Epub 2019 Jan 29.


Nuclear pore density controls heterochromatin reorganization during senescence.

Boumendil C, Hari P, Olsen KCF, Acosta JC, Bickmore WA.

Genes Dev. 2019 Feb 1;33(3-4):144-149. doi: 10.1101/gad.321117.118. Epub 2019 Jan 28.


Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A.

J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.


Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.


Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.

Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M.

Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. doi: 10.1016/j.bbmt.2018.12.069. Epub 2018 Dec 18.


Juvenile dermatomyositis with IgA nephropathy: case-based review.

Mantoo MR, Tripathy SK, Phulware RH, Bagri NK, Hari P, Barwad A.

Rheumatol Int. 2019 Mar;39(3):577-581. doi: 10.1007/s00296-018-4229-4. Epub 2018 Dec 14. Review.


Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome.

Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW.

Biol Blood Marrow Transplant. 2019 May;25(5):921-931. doi: 10.1016/j.bbmt.2018.12.006. Epub 2018 Dec 8.


Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.

Hari P, Blazer M, Raju A, Farrelly E, Labotka R, Skacel T, Romanus D.

Expert Rev Hematol. 2019 Jan;12(1):71-79. doi: 10.1080/17474086.2019.1555460. Epub 2018 Dec 12.


Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A.

Kidney Int. 2019 Jan;95(1):210-218. doi: 10.1016/j.kint.2018.08.039. Epub 2018 Nov 26.


Measuring the Inflammasome in Oncogene-Induced Senescence.

Fernández-Duran I, Tarrats N, Hari P, Acosta JC.

Methods Mol Biol. 2019;1896:57-70. doi: 10.1007/978-1-4939-8931-7_7.


Targeted gene panel for genetic testing of south Indian children with steroid resistant nephrotic syndrome.

Siji A, Karthik KN, Pardeshi VC, Hari PS, Vasudevan A.

BMC Med Genet. 2018 Nov 20;19(1):200. doi: 10.1186/s12881-018-0714-6.


Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2019 Apr;25(4):699-711. doi: 10.1016/j.bbmt.2018.11.004. Epub 2018 Nov 10.


Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2019 Apr;104(4):844-854. doi: 10.3324/haematol.2018.200121. Epub 2018 Oct 31.


Novel biomarkers in multiple myeloma.

Levin A, Hari P, Dhakal B.

Transl Res. 2018 Nov;201:49-59. doi: 10.1016/j.trsl.2018.05.003. Epub 2018 Jun 1. Review.


Posttransplant Lymphoproliferative Disorder: Experience from a Pediatric Nephrology Unit in North India.

Thergaonkar RW, Bhardwaj S, Sinha A, Dinda AK, Kumar R, Bagga A, Srivastava RN, Hari P.

Indian J Nephrol. 2018 Sep-Oct;28(5):374-377. doi: 10.4103/ijn.IJN_143_17.


Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R.

Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.


Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies.

Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN.

Biol Blood Marrow Transplant. 2019 Jan;25(1):e33-e38. doi: 10.1016/j.bbmt.2018.08.031. Epub 2018 Sep 19.


Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.

Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P.

Biol Blood Marrow Transplant. 2019 Feb;25(2):335-342. doi: 10.1016/j.bbmt.2018.09.018. Epub 2018 Sep 20.


Supplemental Content

Support Center